文献速递心境障碍

家用经颅直流电刺激治疗重性抑郁发作:一项随机临床试验

Home-Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

这项双盲、假对照、三臂随机临床试验在巴西纳入210例18至59岁、HDRS-17评分大于16的重性抑郁患者,比较无监督家用tDCS联合数字心理干预、tDCS联合数字安慰剂与双假对照的疗效。第6周HDRS-17评分变化在三组间无统计学显著差异,组间效应量均较小且置信区间跨零,提示无监督家用tDCS未优于假刺激。

要点

  • 无监督家用tDCS联合数字心理干预或数字安慰剂,第6周HDRS-17评分改善均未显著优于假刺激。
  • 双激活组与单tDCS组、双激活组与双假组、单tDCS组与双假组的效应量均小且无统计学意义。
  • 双激活组和单tDCS组皮肤发红及热或烧灼感更常见,单tDCS组发生1例非致命性自杀未遂。

核心结论

  • 无监督家用tDCS联合数字心理干预或数字安慰剂,治疗重性抑郁发作未优于假刺激。

研究设计与样本

  • 双盲、假对照、三臂随机临床试验,2021年4月至2022年10月在巴西圣保罗大学医学院精神病学研究所及受试者家中开展。
  • 筛查837名志愿者,纳入210例18至59岁、HDRS-17评分大于16、至少8年教育且家中可上网并使用智能手机的重性抑郁患者。
  • 随机分为双激活组(n=64)、单tDCS组(n=73)和双假组(n=73),199例完成试验。

主要发现

  • 线性混合效应模型未发现HDRS-17评分在治疗与时间交互作用上存在统计学显著的组间差异。
  • 双激活组 vs 单tDCS组:Cohen d=0.05(95%CI -0.48至0.58;P=.86)。
  • 双激活组 vs 双假组:Cohen d=-0.20(95%CI -0.73至0.34;P=.47)。
  • 单tDCS组 vs 双假组:Cohen d=-0.25(95%CI -0.76至0.27;P=.35)。
  • 双激活组和单tDCS组皮肤发红及热或烧灼感更频繁;单tDCS组发生1例非致命性自杀未遂。

关键数值与推荐

  • tDCS方案:2 mA、30分钟前额叶刺激,连续15个工作日,随后3周每周2次;假刺激为1 mA、90秒。
  • 数字干预为基于行为疗法的46次会话;数字安慰剂为浏览互联网。
  • 主要结局为第6周HDRS-17评分变化。

临床怎么用

  • 本试验条件下,无监督家用tDCS联合或不联合数字心理干预,均未显示优于假刺激的疗效。
  • 临床决策不应基于本试验结果常规推荐无监督家用tDCS治疗重性抑郁发作。
  • 需关注家用tDCS的皮肤不良反应及试验中单tDCS组出现的自杀未遂事件。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transcranial direct current stimulation (tDCS) is moderately effective for depression when applied by trained staff. It is not known whether self-applied tDCS, combined or not with a digital psychological intervention, is also effective. OBJECTIVE: To determine whether fully unsupervised home-use tDCS, combined with a digital psychological intervention or digital placebo, is effective for a major depressive episode. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blinded, sham-controlled, randomized clinical trial with 3 arms: (1) home-use tDCS plus a digital psychological intervention (double active); (2) home-use tDCS plus digital placebo (tDCS only), and (3) sham home-use tDCS plus digital placebo (double sham). The study was conducted between April 2021 and October 2022 at participants' homes and at Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. Included participants were aged 18 to 59 years with major depression and a Hamilton Depression Rating Scale, 17-item version (HDRS-17), score above 16, a minimum of 8 years of education, and access to a smartphone and internet at home. Exclusion criteria were other psychiatric disorders, except for anxiety; neurologic or clinical disorders; and tDCS contraindications. INTERVENTIONS: tDCS was administered in 2-mA, 30-minute prefrontal sessions for 15 consecutive weekdays (1-mA, 90-second duration for sham) and twice-weekly sessions for 3 weeks. The digital intervention consisted of 46 sessions based on behavioral therapy. Digital placebo was internet browsing. MAIN OUTCOMES AND MEASURES: Change in HDRS-17 score at week 6. RESULTS: Of 837 volunteers screened, 210 participants were enrolled (180 [86%] female; mean [SD] age, 38.9 [9.3] years) and allocated to double active (n = 64), tDCS only (n = 73), or double sham (n = 73). Of the 210 participants enrolled, 199 finished the trial. Linear mixed-effects models did not reveal statistically significant group differences in treatment by time interactions for HDRS-17 scores, and the estimated effect sizes between groups were as follows: double active vs tDCS only (Cohen d, 0.05; 95% CI, -0.48 to 0.58; P = .86), double active vs double sham (Cohen d, -0.20; 95% CI, -0.73 to 0.34; P = .47), and tDCS only vs double sham (Cohen d, -0.25; 95% CI, -0.76 to 0.27; P = .35). Skin redness and heat or burning sensations were more frequent in the double active and tDCS only groups. One nonfatal suicide attempt occurred in the tDCS only group. CONCLUSIONS AND RELEVANCE: Unsupervised home-use tDCS combined with a digital psychological intervention or digital placebo was not found to be superior to sham for treatment of a major depressive episode in this trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04889976.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Borrione L, Cavendish BA, Aparicio LVM, et al. Home-Use Transcranial Direct Current Stimulation for the Treatment of a Major Depressive Episode: A Randomized Clinical Trial. JAMA Psychiatry. 2024. PMID: 38170541. doi:10.1001/jamapsychiatry.2023.4948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。